United States - English - NLM (National Library of Medicine)

dava pharmaceuticals, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 4 mg

United States - English - NLM (National Library of Medicine)

unit dose services - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2.5 mg in 3 ml

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components. albuterol sulfate inhalation solution, 0.5%* *potency expressed as albuterol note: the albuterol sulfate inhalation solution contained in the 20 ml multiple-dose bottles is concentrated and must be diluted. read complete instructions carefully before using. 1. draw the appropriate volume of albuterol sulfateinhalation solution, 0.5% into the specially marked dropper that comes with each multidose bottle (figure 1). for children 12 years of age and under, the volume is based upon body weight. use the dropper volume prescribed by your doctor. figure 1 2 . squeeze the solution into the nebulizer reservoir through the appropriate opening, taking care not to touch the tip of the

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease. albuterol sulfate syrup is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components. safety and effectiveness in children below 2 years of age have not been established.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of their components.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

prasco laboratories - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. albuterol sulfate hfa is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. albuterol sulfate hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. for more information, contact the mothertobaby pregnancy studies conducted by the organization of teratology information specialists at 1‑877-311-8972 or visit https://mothertobaby.org/ongoing-study/asthma/. risk summary there are no randomized clinical studies of use of albuterol sulfate during pregnancy. available data from epidemiological studies

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. albuterol sulfate hfa is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. albuterol sulfate hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. for more information, contact the mothertobaby pregnancy studies conducted by the organization of teratology information specialists at 1‑877-311-8972 or visit https://mothertobaby.org/ongoing-study/asthma/. risk summary there are no randomized clinical studies of use of albuterol sulfate during pregnancy. available data from epidemiological studies

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. albuterol sulfate hfa is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older. albuterol sulfate hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . teratogenic effects: pregnancy category c. there are no adequate and well-controlled trials with albuterol sulfate hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital an